Clinical Scorecard: Sleep Apnea’s Billion-Dollar Toll
At a Glance
| Category | Detail |
|---|---|
| Condition | Obstructive Sleep Apnea (OSA) |
| Key Mechanisms | Repeated upper airway obstruction during sleep leading to breathing pauses and excessive daytime sleepiness. |
| Target Population | Working-age adults, particularly those aged 18 to 64 years. |
| Care Setting | Clinical practice with potential for symptom-based screening. |
Key Highlights
- Untreated OSA linked to $180.2 billion productivity losses in the US and £4.22 billion in the UK annually.
- Estimated prevalence of OSA syndrome: 22.8% in the US and 19.5% in the UK.
- Nearly 30% of US adults aged 18-64 and 7% of UK adults in the same age group meet OSA criteria.
- Annual productivity loss per affected worker: $3727.40 in the US and approximately £1840 in the UK.
- Objective sleep testing is essential for diagnosis; symptom-based screening can help identify at-risk individuals.
Guideline-Based Recommendations
Diagnosis
- Use symptom-based proxies for initial screening.
- Objective sleep testing is necessary for definitive diagnosis.
Management
- Continuous positive airway pressure (CPAP) therapy is the primary treatment.
Monitoring & Follow-up
- Assess adherence to CPAP therapy regularly.
Risks
- Potential misclassification due to reliance on symptom-based identification.
Patient & Prescribing Data
Adults with suspected obstructive sleep apnea.
Adherence to CPAP therapy is often suboptimal despite its effectiveness.
Clinical Best Practices
- Implement symptom-based screening in clinical settings to identify at-risk individuals.
- Encourage adherence to CPAP therapy through patient education and follow-up.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
